suPAR and chronic kidney disease—a podocyte story

Martin Zeier, Jochen Reiser

Research output: Contribution to journalReview articlepeer-review

35 Scopus citations


The soluble urokinase-type plasminogen activator receptor (suPAR) is a circulating signaling molecule derived from immature myeloid cells. Elevated levels of suPAR have been linked to the pathogenesis of the kidney disease focal and segmental glomerulosclerosis. Here, suPAR acts on podocytes by activating αvβ3 integrins. Large observational studies showed that suPAR also predicts chronic kidney disease incidence and progression by predating the disease by several years prior to any other known marker of renal dysfunction. suPAR is rapidly developing into a prime target for pharmacotherapy as its neutralization is forecasted to be feasible and safe.

Original languageEnglish (US)
Pages (from-to)1017-1020
Number of pages4
JournalPflugers Archiv European Journal of Physiology
Issue number7-8
StatePublished - Aug 1 2017
Externally publishedYes


  • CKD
  • FSGS
  • Integrin
  • Podocyte
  • suPAR

ASJC Scopus subject areas

  • Physiology
  • Clinical Biochemistry
  • Physiology (medical)


Dive into the research topics of 'suPAR and chronic kidney disease—a podocyte story'. Together they form a unique fingerprint.

Cite this